Denali Advisors LLC Purchases Shares of 10,251 Organon & Co. $OGN

Denali Advisors LLC acquired a new stake in shares of Organon & Co. (NYSE:OGN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,251 shares of the company’s stock, valued at approximately $99,000.

A number of other institutional investors have also recently made changes to their positions in OGN. Hanson & Doremus Investment Management purchased a new position in shares of Organon & Co. during the second quarter valued at about $26,000. Ransom Advisory Ltd purchased a new position in shares of Organon & Co. during the first quarter valued at about $32,000. Brooklyn Investment Group grew its position in shares of Organon & Co. by 1,012.3% during the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after purchasing an additional 2,794 shares in the last quarter. Ridgewood Investments LLC purchased a new position in shares of Organon & Co. during the second quarter valued at about $48,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Organon & Co. during the first quarter valued at about $51,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Up 1.2%

Shares of NYSE OGN opened at $9.05 on Friday. The business’s 50 day moving average is $9.92 and its two-hundred day moving average is $9.93. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $19.05. The stock has a market capitalization of $2.35 billion, a P/E ratio of 3.36, a PEG ratio of 0.81 and a beta of 0.63.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.55 billion. During the same period in the previous year, the firm posted $1.12 earnings per share. The firm’s revenue for the quarter was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 15th. Organon & Co.’s payout ratio is presently 2.97%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Organon & Co. has an average rating of “Moderate Buy” and an average target price of $17.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.